Use of Adelmidrol in the Treatment of Epithelial Dysfunctions

Abstract

Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

What is claimed is: 
     
         1 . A method of increasing the endogenous levels of palmitoylethanolamide without inhibiting the activity of the palmitoylethanolamide-degrading FAAH and NAAA enzymes in a human being or animal affected by an epithelial tissue dysfunction comprising bladder inflammation, the method comprising
 administering Adelmidrol, wherein Adelmidrol causes the palmitoylethanolamide endogenous levels to increase.   
     
     
         2 . The method according to  claim 1 , wherein said Adelmidrol is administered in a combined, sequential, or separate manner in combination with at least one active ingredient selected from the group consisting of 2-pentadecyl-2-oxazoline of palmitoylethanolamide, an anti-microbial agent, trans-traumatic acid and hyaluronic acid or derivatives thereof. 
     
     
         3 . The method according to  claim 2 , wherein said anti-microbial agent is selected from  Echinacea purpurea  extract,  Usnea barbata  extract, usnic acid, phytosphingosine, bronopol and mixtures thereof. 
     
     
         4 . The method according to  claim 2 , wherein hyaluronic acid and trans-traumatic acid are present in the sodium hyaluronate trans-traumatate double salt form. 
     
     
         5 . The method according to  claim 1 , wherein the amount of Adelmidrol to be administered in the form of solutions intended for the epithelia ranges between 0.5 and 20 mg/Kg body weight. 
     
     
         6 . A method of increasing the endogenous levels of palmitoylethanolamide without inhibiting the activity of the palmitoylethanolamide-degrading FAAH and NAAA enzymes in a human being or animal affected by an epithelial tissue dysfunction comprising bladder inflammation, the method comprising administering a pharmaceutical formulation containing Adelmidrol and one or more active ingredients selected from the group consisting of 2-pentadecyl-2-oxazoline of palmitoylethanolamide, an anti-microbial agent, trans-traumatic acid, and hyaluronic acid. 
     
     
         7 . The method according to  claim 6 , wherein said formulation has the following weight composition, the balance being relative only to the active ingredients: 
       
         
           
                 
                 
                 
               
                     
                     
                 
                     
                   Adelmidrol 
                   50-100%   
                 
                     
                   2-pentadecyl-2-Oxazoline of PEA 
                   0-5% 
                 
                     
                   Hyaluronic acid 
                   0-5% 
                 
                     
                   Trans-traumatic acid 
                   0-5% 
                 
                     
                   Anti-microbial agent 
                    0-1%. 
                 
                     
                     
                 
             
                
               
               
                
                
                
                
                
                
               
            
           
         
       
     
     
         8 . The method according to  claim 6 , wherein said anti-microbial agent is selected from  Echinacea purpurea  extract,  Usnea barbata  extract, usnic acid, phytosphingosine, bronopol and mixtures thereof. 
     
     
         9 . The method according to  claim 6 , wherein hyaluronic acid and trans-traumatic acid are present the sodium hyaluronate trans-traumatate double salt form. 
     
     
         10 . The method according to  claim 6 , wherein the weight concentration of Adelmidrol in the pharmaceutical forms for topic application for use in both human beings and animals ranges between 0.2% and 7.0%, and the weight concentration of Adelmidrol in the solutions for application on internal epithelia ranges between 0.3% and 5.0%. 
     
     
         11 . A method of treating bladder inflammation, the method comprising administering to a subject affected by bladder inflammation an effective amount of Adelmidrol so as to increase endogenous levels of palmitoylethanolamide without inhibiting the activity of palmitoylethanolamide-degrading FAAH and NAAA enzymes in the subject, and thereby treating bladder inflammation in the subject, wherein the subject is a human being or animal.